Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 12Recruiting 10Unknown 5Not yet recruiting 5Active not recruiting 2Terminated 1Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 3Glioma 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenoviridae Infections 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Mesothelioma, Malignant 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Graft vs Host Disease 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Enrolling by invitation × Solid Tumors × Clear all
NCT06992687 2025-05-28

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 1/2 Enrolling by invitation
30 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡